Quick Answer
Outlook Therapeutics, Inc. reported Total Revenue of $1.41 million for fiscal year 2025.
Outlook Therapeutics, Inc. Total Revenue — Annual History
| Fiscal Year | Total Revenue | YoY Change |
|---|---|---|
| 2025 | $1.41M | -82.6% |
| 2019 | $8.15M | +163.8% |
| 2018 | $3.09M | -19.0% |
| 2017 | $3.81M | +27.9% |
| 2016 | $2.98M | -42.9% |
| 2015 | $5.22M | — |
Quarterly Total Revenue
| Quarter Ending | Total Revenue | YoY | QoQ |
|---|---|---|---|
| June 30, 2025 | $1.51M | — | +157.8% |
| June 30, 2019 | $583.8K | -24.4% | -8.9% |
| March 31, 2019 | $641.1K | -16.9% | -39.9% |
| December 31, 2018 | $1.07M | +38.3% | +38.3% |
| June 30, 2018 | $771.9K | +154.6% | +0.0% |
| March 31, 2018 | $771.9K | +154.6% | +0.0% |
| December 31, 2017 | $771.9K | +154.6% | +154.6% |
| June 30, 2017 | $303.1K | -38.7% | +0.0% |
- Outlook Therapeutics, Inc. showed a decrease of -82.6% in Total Revenue compared to the prior fiscal year.
- Over the 2015–2025 period, Outlook Therapeutics, Inc.’s total revenue has declined by 72.9% (from $5.22 million to $1.41 million).
- The most recent figure is from Outlook Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on December 19, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: